NC
CABA icon

nVerses Capital’s Cabaletta Bio CABA Stock Holding History

nVerses Capital’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.1K Buy
+20,286
New +$66.7K 0.1% 261
2024
Q4 		– Sell
-3,000
Closed -$14.2K – 134
2024
Q3 		$14.2K Buy
+3,000
New +$17.4K 0.01% 852

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

nVerses Capital's CABA Position: Q2 2026 in Review

nVerses Capital opened a new position in Cabaletta Bio (CABA) in Q2 2026: 20,286 shares worth $63.1K. The stake represents 0.1% of the portfolio and ranks #261 among its holdings. This is a return to the name: nVerses Capital previously reported a position in CABA as recently as Q3 2024.

nVerses Capital first reported a position in CABA in Q3 2024 and has held it in 2 quarters since. 139 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • nVerses Capital held 20,286 shares of Cabaletta Bio worth $63.1K as of Q2 2026.
  • Cabaletta Bio was a new nVerses Capital position in Q2 2026.
  • Cabaletta Bio made up 0.1% of nVerses Capital's portfolio in Q2 2026, its #261 holding.
  • nVerses Capital first reported a position in Cabaletta Bio in Q3 2024 and has held it in 2 quarters since.
  • 139 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.